Welcome to our dedicated page for Bausch + Lomb news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb stock.
Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb (NYSE/TSX: BLCO) has launched Blink NutriTears, a new clinically proven over-the-counter supplement for dry eyes in the U.S. This product targets the root causes of dry eyes and promotes healthy tear production, providing relief within two to four weeks. The supplement contains lutein, zeaxanthin, curcumin, and vitamin D, shown to improve ocular symptoms and tear film homeostasis. Clinical studies indicate NutriTears can keep tears on the eyes 33% longer, offering significant symptom relief. It will be available in the eye care aisle and online at major retailers by the end of July.
Bausch + Lomb, a global eye health company, announced the results of its 2024 annual shareholder meeting held on May 29, 2024. All 10 nominated directors were elected. Key votes included Nathalie Bernier, Gary Hu, Brett Icahn, Sarah B. Kavanagh, Karen L. Ling, John A. Paulson, Russel C. Robertson, Thomas W. Ross Sr., Brenton L. Saunders, and Andrew C. von Eschenbach.
Shareholders approved executive compensation in a non-binding advisory vote and an amendment to the 2022 Omnibus Incentive Plan, increasing the number of shares authorized for issuance. PricewaterhouseCoopers LLP was appointed as the independent registered public accounting firm until the 2025 annual meeting. The final vote results will be filed with the SEC on Form 8-K and will be available on the company's SEDAR+ profile and website.
Bausch + Lomb announced the presentation of new scientific data at the American Optometric Association's Optometry’s Meeting. Scheduled events include 12 ePosters and 3 live presentations, highlighting products like MIEBO, Blink NutriTears, and INFUSE. Key presentations will cover clinical data on Blink Triple Care Lubricating Eye Drops and Biotrue Hydration Plus Multi-Purpose Solution. The company will also host nine educational events. MIEBO and XIIDRA's benefits for dry eye disease and other eye health products will be discussed.
Bausch + Lomb (NYSE/TSX: BLCO) has received Health Canada approval for its new enVista® Envy™ intraocular lens (IOL), marking the first global regulatory approval of this product. The enVista Envy IOL offers a full visual range with high tolerance to dysphotopsia. Clinical trials in Canada showed excellent long-term outcomes, with 93% of patients reporting minimal visual disturbances and 94% experiencing little to no difficulty viewing close objects while achieving excellent distance vision without glasses. The lens features ActivSync Optic Intelligent Energy Distribution and ClearPath technology, enhancing vision in varying lighting conditions and reducing light scattering. Commercial availability in Canada is set for mid-June, with plans for additional regulatory approvals in the U.S. and Europe.
Bausch + Lomb (NYSE/TSX: BLCO) reported first-quarter 2024 results, with revenue reaching $1.099 billion, a GAAP net loss of $167 million, and an adjusted EBITDA of $180 million. The revenue grew by 18% as reported and 20% on a constant currency basis compared to the first quarter of 2023. The company experienced broad-based growth across all business segments and key franchises, with strong performance in Vision Care, Surgical, and Pharmaceuticals segments. The positive financial results were driven by growth in Daily SiHy lenses, LUMIFY, and eye vitamins, along with successful launches of MIEBO and XIIDRA. Bausch + Lomb also raised its full-year 2024 constant currency revenue growth guidance.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.